InvestorsHub Logo
Followers 0
Posts 213
Boards Moderated 0
Alias Born 07/31/2017

Re: None

Wednesday, 07/18/2018 1:39:34 PM

Wednesday, July 18, 2018 1:39:34 PM

Post# of 18220
The Shareholder's Letter from Griffin indicated as a strategic objective for 2018 a Board of Directors approval for a search for a new CEO replacing the wholly unqualified Griffin and a new CMO (Chief Medical Officer). The Company's goal was to fill both of these roles by the end of Q2 of 2018. Lo and behold we are 18 days past that goal and there is absolutely no doubt the goals are nowhere near completion. As an aside, flying under the radar is the fact that a very significant position in a Biotechnology company is the CMO. What happened to Angus G. Dalgliesh, M.D.? Remember him-he was the CMO. What happened? I know where he is and doing excellent and very meaningful research on LDN: Department of Oncology, Institute for Infection and Immunity, St. George's University of London, London, UK.

Why no longer CMO of IMUN??

Want some real news to have the stock immediately rise in value-it would be the attainment of the aforementioned goals ASAP. But the replacements must be with qualified and proven individuals. They are out there!

And finally, and once again, what happened to the highly touted John Abeles, M.D. and the proposed initiatives as a result of the January, 2018 Meeting with the FDA.?? Same question-What Happened??